You're viewing our updated article page. If you need more time to adjust, you can return to the old layout.

ERRATUM article

Front. Pharmacol., 09 January 2023

Sec. Pharmacology of Anti-Cancer Drugs

Volume 13 - 2022 | https://doi.org/10.3389/fphar.2022.1123234

Erratum: Advances in RIPK1 kinase inhibitors

    FP

    Frontiers Production Office

  • Frontiers Media SA, Lausanne, Switzerland

Article metrics

View details

2

Citations

3,6k

Views

3,1k

Downloads

Due to a production error, the list of affiliations used for the authors was incorrect. The correct affiliations list is shown below.

Lu Chen1,2,†, Xiaoqin Zhang3,†, Yaqing Ou4,†, Maoyu Liu1,2,†, Dongke Yu1,2, Zhiheng Song5, Lihong Niu6,*, Lijuan Zhang1,2,* and Jianyou Shi1,2,*

1Department of Pharmacy, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China

2Personalized Drug Therapy Key Laboratory of Sichuan Province, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China

3Department of Critical Care Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan, China

4Department of Pharmacy, The Affiliated Chengdu 363 Hospital of Southwest Medical University, Chengdu, Sichuan, China

5Suzhou University of Science and Technology, Suzhou, Jiangsu, China, 6 Institute of Laboratory Animal Sciences, Academy of Medical Sciences and Sichuan Provincial People’s Hospital, Chengdu, Sichuan, China

The publisher apologizes for this mistake. The original version of this article has been updated.

Summary

Keywords

inhibitor, receptor interacting protein 1 (RIP1), programmed necrosis, necrosis, RIP1 (RIPK1)

Citation

Frontiers Production Office (2023) Erratum: Advances in RIPK1 kinase inhibitors. Front. Pharmacol. 13:1123234. doi: 10.3389/fphar.2022.1123234

Received

13 December 2022

Accepted

13 December 2022

Published

09 January 2023

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

13 - 2022

Updates

Copyright

*Correspondence: Frontiers Production Office,

This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics